Clinical data published in Clinical Microbiology and Infection supports the use of MeMed testing to reduce the overuse of antibiotics in children
The study proves the test's high performance in distinguishing bacterial and viral infections
Include a broad range of pediatric populations with fever and passive and respiratory infections
MeMed's test is superior to existing biomarkers of infection
Haifa, Israel, Boston, Massachusetts; December 1, 2021-MeMed, a leader in the emerging field of advanced host response technology, today announced the positive results of AutoPilot. This is a prospective, multicenter study that evaluates The performance of the MeMed test in distinguishing bacterial and viral infections. The research was funded by the European Commission and has been published in "Clinical Microbiology and Infection".
In the AutoPilot study, the high diagnostic performance of host reactive protein characteristics based on MeMed technology was verified in a wide range of pediatric cohorts (n=1,008; >90 days to 18 years old). In emergency departments and wards in Italy and Germany, the test demonstrated the potential to improve antibiotic management in children with passive and respiratory infections with fever.
Dr. Eran Eden, Co-founder and CEO of MeMed, said: “Data drives everything we do at MeMed. This is the largest pediatric prospective study of our technology so far, and it has been Part of the growing evidence base generated by the clinical team has established the high performance and practicality of our technology. We thank the European Commission for funding this research and our clinical collaborators who led this research.”
Tobias Tenenbaum, Professor of Medicine, Tobias Tenenbaum, head of the Sana Klinikum Lichtenberg Children’s and Adolescent Medicine Clinic and Chairman of the German Society of Pediatric Infectious Diseases (DGPI), said: “I often treat fever without obvious origin, diagnosis Uncertain children. Although we want to reduce the inappropriate use of antibiotics, we don’t want bacterial infections to go untreated. This study shows that doctors now have a new option to potentially improve the prognosis of patients. Biomarkers The signature may reduce the overtreatment of children with antibiotics by more than three times without affecting the underuse. These data indicate that host response testing plays an important role in the treatment of acute infections in children."
Professor Susanna Esposito, full professor of pediatrics at the University of Parma and director of the pediatric clinic, said: “In Italy, we are struggling to cope with rising antimicrobial resistance and are making considerable efforts to use antibiotics sparingly. That’s why I’m so happy to be able to use antibiotics. Working with MeMed to establish the accuracy of the MeMed test on patients in our center. The impressive performance data in the AutoPilot study will promote the adoption of this test, which I believe will promote the use of appropriate antibiotics."
Bacterial and viral infections are usually indistinguishable clinically, leading to the prescription of antibiotics for children with viral infections, but antibiotics are ineffective. The abuse of antibiotics has led to the emergence of antimicrobial resistance (AMR), which is one of the greatest healthcare challenges of our time.
Our mission is to transform the complex signals of the immune system into simple insights, thereby changing the diagnosis and treatment of diseases, and benefiting patients and society a lot. To learn more about MeMed and our solutions, please visit http://www.me-med.com
About MeMed BV® MeMed BV® is the first immune-based protein signature test of its kind, developed and validated during a ten-year collaboration with leading academic and commercial partners. It provides doctors with an indispensable tool that can help distinguish bacterial and viral infections from multiple pathogens, even if the site of infection is inaccessible or unknown. MeMed BV® measures and calculates the level of integrated three immune system proteins: TRAIL, IP-10 and CRP. When running on the MeMed Key® platform, MeMed BV® provides results within 15 minutes. MeMed BV® has been independently verified on thousands of patients and the results have been published in leading peer-reviewed journals (including Pediatrics, The Lancet ID, PLOS One, BMJ Peds, European Journal of Clinical Microbiology & Infectious Diseases and Clinical Microbiology and Infection. The MeMed BV® test has obtained 510(k) approval from the US FDA, CE mark in Europe, and AMAR approval from the Israeli Ministry of Health. Within minutes, a variety of proteins can be measured when needed. It opens up the quantification of health and disease The path to a large number of human proteins in the state is actually important no matter when and where it is. The MeMed Key® development plan has been partially funded and approved by the US Department of Defense and the European Commission. MeMed Key® has received the US FDA’s 510( k) Approval, European CE mark and AMAR approval H from the Israeli Ministry of Health.
MeMed Contact: Will Harris, Vice President of Marketing, MeMed pr@me-med.com Kfir Emmer, Chief Financial Officer, MeMed kfir.emmer@me-med.com Media Relations Contact: Consilium Strategic Communication MeMed@consilium-comms. com
MeMed Autopilot Publication Final Edition-German
MeMed Autopilot publication PR ITALIAN
After test results showed that omicron might evade some of the protection provided by Pfizer's Covid vaccine, vaccine stocks fell on Tuesday.
Vir Biotechnology and GlaxoSmithKline’s COVID-19 antibody treatments work on omicron in laboratory studies.
(Bloomberg)-Former U.S. Secretary of State Rex Tillerson was diagnosed with kidney cancer a few months after being fired by then President Donald Trump through a tweet in 2018 in the infamous 2018. Troops are stationed to protect tourists in Cancun. Even in Metaverse, not all identities are equal. The US$300 billion plan to bring green energy to China’s megacities meets new climate refugees in cities and towns: CoyotesT
With a few exceptions for emergency or urgent care, the Medicare plan only covers you in the United States and its territories. But when you move abroad, should you keep insurance? Expert Ron Elledge answered some common questions.
GlaxoSmithKline (GlaxoSmithKline) is seeking to approve the world's first plant-based vaccine as it scrambles to catch up with its competitors in the race to treat the new coronavirus.
The second batch of preclinical data shows that sotrovimab is effective against all 37 mutations identified so far in the Omicron spike protein.
According to doctors and data, you can expect the side effects of COVID-19 boosters from Pfizer, Moderna, and Johnson & Johnson. It is now recommended that everyone over 18 years of age get COVID-19 booster shots.
Dr. Stephen Hoge, President of Moderna, said on Sunday that the effectiveness of its vaccine may be reduced due to Omicron.
In the past week, the global war against COVID-19 has changed - and just last weekend it has changed dramatically.
After Merck's Covid pill, Monoprevir, is reviewed by an FDA consultant, will it be bought or sold? Is MRK stock now bought or sold?
Republicans’ trust in doctors is waning. This is a symptom of a larger disease.
A briefing document issued on Monday indicated that the FDA may not approve Reata Pharma's kidney disease treatment—and RETA stock plummeted.
Author: David Bautz, Ph.D. Nasdaq: ARWR Read the full ARWR research report and GlaxoSmithKline’s ARO-HSD business renewal license agreement; interim clinical data announced at the Liver Conference November 22, 2021, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that it has reached a license agreement with GlaxoSmithKline (GSK) for ARO-HSD. Arrowhead’s research RNAi therapeutics are currently under development.
The share price of Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biopharmaceutical company, fell today due to mixed clinical trial data. As of 11:53 AM Eastern Time on Monday, investors were nervous about the future of the company's main candidate, pushing the stock down 36.6%. Aegla BioTherapeutics' main drug candidate, PEGylation, is an enzyme replacement therapy for patients with a rare amino acid metabolism disorder called arginase 1 deficiency.
After the emergence of a new Covid variant that may cancel its Covid vaccine, is Pfizer's stock worth buying? Can PFE stocks be bought now?
A new study shows that Viagra may be able to protect people from Alzheimer's disease.
According to scientists, a rare heart-related health condition caused by the Covid-19 vaccine is mild and will subside quickly.
CVS has always been an important assistant in the fight against COVID, providing vaccination, testing, and pandemic essentials at nearly 10,000 locations across the United States. Although the pharmacy chain recently announced plans to close 900 stores in the next few years, it still strives to help the local community maintain Health-this goes far beyond the current pandemic. In fact, CVS has just issued an emergency warning to all customers who might send you directly to the nearest location. continue reading
Your risk of dementia is related to a series of factors-some of which, such as age and genetics, are completely out of your control. However, experts say that certain common habits can significantly increase your risk of developing progressive and incurable diseases. In fact, current research warns that one thing you might do in the bathroom can cause your risk of dementia to skyrocket. They say that this habit may increase your risk of dementia by 65% compared to following your doctor’s advice
Acadia Pharmaceuticals (NASDAQ: ACAD) shares rose 19.2% in premarket trading on Tuesday morning. The biotech company's stock rose today in response to positive clinical readings of its experimental Rett syndrome drug trofetide. Rett syndrome is a rare genetic disorder characterized by progressive deterioration of motor and language skills.